Humasis Co. Ltd.

KOSDAQ 205470.KQ

Humasis Co. Ltd. Capital Expenditure for the year ending December 31, 2023: USD -17.91 M

Humasis Co. Ltd. Capital Expenditure is USD -17.91 M for the year ending December 31, 2023, a 49.22% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Humasis Co. Ltd. Capital Expenditure for the year ending December 31, 2022 was USD -35.26 M, a -132.57% change year over year.
Humasis Co. Ltd. Capital Expenditure for the year ending December 31, 2021 was USD -15.16 M, a -10.40% change year over year.
Humasis Co. Ltd. Capital Expenditure for the year ending December 31, 2020 was USD -13.73 M, a -427.67% change year over year.
Humasis Co. Ltd. Capital Expenditure for the year ending December 31, 2019 was USD -2.60 M, a -193.98% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

KOSDAQ: 205470.KQ

Humasis Co. Ltd.

CEO	Sung-gon Kim
IPO Date	Sept. 27, 2017
Location	South Korea
Headquarters	504, Shinwon Vision Tower
Employees	105
Sector	Consumers Staples
Industries Personal Care 3D Printing Biotechnology Cleaning Supplies Fertilizers Hardware & Electronics Medical Instruments Pharmaceuticals

Description

Humasis Co. Ltd. develops, manufactures, and markets in-vitro diagnostics for the detection of cardiac marker, fertility hormone, infectious disease, tumor marker, and cotinine for home and laboratory use in South Korea and internationally. It offers pregnancy and ovulation self-test products; Hubi-Quan Pro, a self-contained and cartridge reader to provide rapid quantitative results for membrane-based lateral flow immunochromatographic assays; and various rapid test kits. The company was founded in 2000 and is based in Anyang, South Korea.

Key trends

Past 5 years